This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoit, B. D. Search for Related Content PubMed PubMed Citation Articles by Hoit, B. D.

(Circulation Research. 2001;89:289.)
© 2001 American Heart Association, Inc.

Editorial

Two Faces of Nitric Oxide

Lessons Learned From the NOS2 Knockout

Brian D. Hoit

From the Department of Medicine, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio.

Correspondence to Brian D. Hoit, MD, Division of Cardiology, Case Western Reserve University, 11100 Euclid Ave, MS 5038, Cleveland, OH 44106-5038. E-mail bdh6@po.cwru.edu

Key Words: nitric oxide synthase • myocardial infarction • remodeling • apoptosis • contractility

Nitric oxide synthases (NOSs) comprise a family of enzymes that generate the freely diffusible, free radical gas NO, by the conversion of L-arginine to L-citrulline in the presence of O₂ and NADPH. Bioactive derivatives of NO (NOx) are produced depending on the redox state of the cell and the availability of substrates and cofactors.¹ The three NOSs arise from separate genes, but each NOS molecule is composed of a calmodulin binding domain that links a carboxyl terminal flavin-containing reductase domain with an amino terminal heme-containing oxygenase domain.¹ Neuronal NOS (or NOS1) and endothelial NOS (or NOS3) are constitutively active isoforms with calmodulin binding (and, consequently, enzyme activity) regulated by physiological [Ca²⁺], whereas inducible NOS (iNOS or NOS2) binds calmodulin tightly, even at physiological [Ca²⁺].¹

Each of the three NOS isoforms is present in the heart, undergoes posttranslational modification, and is spatially constrained within the cell. NOS1 expression is limited and its physiological role is unclear. The largest sources in the heart of the cytokine (interleukin-1ß [IL-1ß], tumor necrosis factor- [TNF-], interferon- [IFN-], interleukin-6 [IL-6]) and lipopolysaccharide-inducible NOS2 are from cardiac myocytes, endothelial cells, and infiltrating macrophages. NOS3 is found in the endocardial and coronary arterial endothelium, myocytes, and specialized cardiac conduction tissue.¹

Constitutive expression of NO is protective. Vascular effects include vasodilatation, inhibition of platelet adhesion and neutrophil infiltration, prevention of neointimal proliferation, and inhibition of vascular remodeling in heart. Cardiac effects of constitutive NO include regulation of the coronary circulation, heart rate, and . . . [Full Text of this Article]

This article has been cited by other articles:

				R. van Haperen, M. de Waard, E. van Deel, B. Mees, M. Kutryk, T. van Aken, J. Hamming, F. Grosveld, D. J. Duncker, and R. de Crom Reduction of Blood Pressure, Plasma Cholesterol, and Atherosclerosis by Elevated Endothelial Nitric Oxide J. Biol. Chem., December 6, 2002; 277(50): 48803 - 48807. [Abstract] [Full Text] [PDF]